ALHC vs MRK
Alignment Healthcare, Inc. vs Merck & Co. — AI-powered side-by-side comparison
ALHC
Alignment Healthcare, Inc.
54
Watch
VS
| Metric | ALHC | MRK |
|---|
| AI Score |
54
|
70
|
| Price |
$13.18
|
$130.34
|
| P/E Ratio |
66.17×
|
103.53×
|
| ROE |
-0.4%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
12.5%
|
75.4%
|
| Debt / Equity |
1.25×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
23.3
|
64.5
|
| Beta |
1.101
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ALHC versus MRK.
MRK leads by 16 points.
MRK scores 70/100 (Buy) versus ALHC at 54/100 (Watch).
ALHC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 37.2% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.80) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 20.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 37.2% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 70.2 is expensive by classic value standards — Value
- Price-to-book of 22.0x prices in significant intangible value — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical